## **CERTIFICATIONS**

(company name)	, through the undersigned authorized representative, hereby
certifies that:	
· · ·	ates and forms may be disapproved, or otherwise give rise to disable law or regulations. <i>See, e.g.,</i> 40 P.S. § 3801.304(b).
condition of the Company, or knowingly making any f Company, or knowingly omitting to make a true entr	nowingly making any false material statement as to the financial false entry of material fact in any book, report or statement of the y of any material fact pertaining to the Company in a book, report an unfair method of competition and unfair or deceptive act or 171.5(a)(5).
AND further certifies, as to the below-referenced pol	icy form, along with any related rate filing, that:
1. Rates and	l Forms Generally
P.L. 111-148,124 Stat. 119, and the Health Care and E	e requirements of the Patient Protection and Affordable Care Act, Education Reconciliation Act of 2010, P.L. 111-152, 124 Stat. 1051, If the regulations and federal guidance promulgated thereunder.
$\square$ The Compliance Checklist submitted with the police	cy form is true, correct and complete.
certify the representations of the Company as set f this Certification Form (relative to statements above correct, and complete.	, hereby warrant that I have full, complete and final authority to forth herein, that the certifications and representations set forth in we regarding Certifications and Rates and Forms General) are true,
Policy Form #	
Date Na	me and Title of Authorized Representative of the Company
Się	gnature of Authorized Representative of the Company

## 2. Mental Health and Substance Use Disorder Coverage Parity

as amended by the ACA, including the financial re	the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), equirements (FR), quantitative treatment limitations (QTLs), and non-ental Health or Substance Use Disorder Coverage (MH/SUD).
· · · · · · · · · · · · · · · · · · ·	NQTL applicable to MH/SUD benefits, as written and as to be applied, is ne classification, and that such parity is demonstrated by a documented
FR or QTL of that type applied to substar FR or QTL is considered to apply to "subs at least two-thirds of the benefits in the medical/surgical benefits in a classification	efits in any classification is not more restrictive than the predominant intially all medical/surgical benefits in the same classification, where: an stantially all" medical/surgical benefits in a classification if it applies to classification; and, if the FR or QTL applies to substantially all on, the predominant level of the FR or QTL is the level that applies to ical benefits in the classification subject to the FR or QTL.
to be in operation, any processes, strate to MH/SUD benefits in the classification	nefits in any classification, under the terms of the policy as written and egies, evidentiary standards, or other factors used in applying the NQTL are comparable to, and are intended to be applied no more stringently ary standards, or other factors used in applying the NQTL to ation.
certify the representations of the Company as s	, hereby warrant that I have full, complete and final authority to set forth herein, that the certifications and representations set forth in th and Substance Use Disorder Coverage Parity) are true, correct, and
Policy Form #	
Date	Name and Title of Authorized Representative of the Company

Signature of Authorized Representative of the Company

## 3. Opioid Crisis Response

	nsistent with Act 146 of 2022 and the Department of Human Services' Bulletin Notices reatment, MAB2024020601 (pa.gov)):
authorization, including covera	rescription drug combination product;
	hine/naloxone prescription drug combination product; injectable and oral naltrexone; benefit on the policy's lowest non-preventive cost tier, as applicable.
☐ Covers sublingual buprenorphing	ne opioid use disorder treatment that exceeds a daily dose of 24 mg/day
medical standards, are consiste service in a clinically appropriat	criteria adopted by the Company are based on applicable nationally recognized ant with applicable governmental guidelines, provide for the delivery of a health care see type, frequency and setting and for a clinically appropriate duration, and reflect the vidence regarding emerging procedures, clinical guidelines and best practices as er-reviewed medical literature.
certify the representations of the	tive's name), hereby warrant that I have full, complete and final authority t e Company as set forth herein, that the certifications and representations set forth i o the Opioid Crisis Response) are true, correct, and complete.
 Date	Name and Title of Authorized Representative of the Company
	Signature of Authorized Representative of the Company